PD-L1 expression was more common among patients with the GCB subtype of diffuse large B-cell lymphoma, and PD-L1 positivity predicted shorter survival.
Diffuse Large B-Cell Lymphoma
CAR T cells targeting CD19 can be effective at treating relapsed/refractory diffuse large B-cell lymphoma or follicular lymphoma, with high rates of durable remission.
History of Epstein-Barr virus or immunosuppression did not affect outcomes for patients with diffuse large B-cell lymphoma.
In those with DLBCL, Burkitt lymphoma, and Hodgkin lymphoma, cure is often achieved. Furthermore, in the salvage setting, whether auto-HCT or allo-HCT is used, the same appears to be true. A great deal of progress has been made in the treatment of lymphoma in patients with HIV infection, but more remains to be done before outcomes are comparable to those of the general population.
In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.
In this interview, we discuss the biology and the therapeutic strategies for primary mediastinal B-cell lymphoma.
Two-year survivors with relapsed Hodgkin lymphoma or diffuse large B-cell lymphoma after transplant had an excess late mortality risk vs the general population.
Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
The number of extranodal sites of disease did not influence outcomes among young patients with high-risk DLBCL treated with rituximab-dose-dense chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation.
Elderly patients, including those treated with an R-CHOP regimen, tend to have poor outcomes regardless of salvage therapy.